TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7634752

Group type: EXPERIMENTAL
Intervention: High doses of insulin-like growth factor I (30 micrograms h-1 kg-1) and insulin (0.23 nmol h-1 kg-1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low doses of insulin-like growth factor I (5 micrograms h-1 kg-1) and insulin (0.04 nmol h-1 kg-1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 3
Study: 2694482

Group type: EXPERIMENTAL
Intervention: Mefloquine alone (250 mg/week)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Mefloquine, sulfadoxine (500 mg/week), and pyrimethamine (25 mg/week) (MSP)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mefloquine alone
Number of subjects: 175
Study: 793186

Group type: EXPERIMENTAL
Intervention: Ketoprofen (2 X 50 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Phenylbutazone (2 X 300 mg daily)
Number of subjects: 46
Study: 31132159

Group type: EXPERIMENTAL
Intervention: 6-month recall period survey
Number of subjects: 2425

Group type: COMPARATOR
Intervention: 12-month recall period survey
Number of subjects: 2425
Study: 29738183

Group type: EXPERIMENTAL
Intervention: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid for 4 weeks
Number of subjects: 225

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd for 4 weeks
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid after 4 weeks of treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd after 4 weeks of treatment
Number of subjects: 225
Study: 25885780

Group type: EXPERIMENTAL
Intervention: Locally‐made low‐tech rocket stove
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imported, highly efficient Philips gasifier stove
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 24192134

Group type: EXPERIMENTAL
Intervention: Nutrition education (group presentations, individual consultations, detailed information)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Nutrition education and environmental dietary modification (restriction of fat, saturated fat, sugar, and salt; increase in fibre, fruit, and vegetables; price discounts for whole fresh fruit; strategic positioning of healthier alternatives; portion size control)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Environmental dietary modification alone
Number of subjects: 448

Group type: COMPARATOR
Intervention: No intervention (Control group in Workplace A)
Number of subjects: 448
Study: 21441550

Group type: COMPARATOR
Intervention: Etanercept (TNF-α inhibitor)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Infliximab (TNF-α inhibitor)
Number of subjects: 230
Study: 19587779

Group type: EXPERIMENTAL
Intervention: CX3CR1 V249I and T280M polymorphisms
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: CX3CL1 levels
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Genotype or haplotype frequencies
Number of subjects: 368
Study: 17174773

Group type: EXPERIMENTAL
Intervention: Intraoperative awakening with conscious analgo-sedation in group A (76 patients)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group B (73 patients)
Number of subjects: 149
Study: 15187323

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment with different initial UV doses, treated twice a week for up to 30 sessions.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment for acral and joint areas.
Number of subjects: 69
Study: 11502230

Group type: EXPERIMENTAL
Intervention: 50 g glucose drink
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 g glucose drink (informed)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aspartame drink (informed)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aspartame drink (misinformed)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 g glucose drink (misinformed)
Number of subjects: 26
Study: 9924240

Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia (PCIA) with 0.2% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with nicomorphine
Number of subjects: 60
Study: 8064736

Group type: EXPERIMENTAL
Intervention: Zinc acexamate (ZAC) 300 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 10291784

Group type: EXPERIMENTAL
Intervention: Oncology nurse specialist with continuing education on cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing education on cancer alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation only group
Number of subjects: 0
Study: 31706786

Group type: EXPERIMENTAL
Intervention: Low dose lurasidone (80mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High dose lurasidone (240mg)
Number of subjects: 42
Study: 31170870

Group type: EXPERIMENTAL
Intervention: Aerobic exercise session (AER)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Aerobic exercise session with coordinative demands (AER+C)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 106
Study: 26918471

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Titanium
Number of subjects: 52
Study: 25692369

Group type: EXPERIMENTAL
Intervention: Incidental Durotomy
Number of subjects: 409

Group type: COMPARATOR
Intervention: No Incidental Durotomy
Number of subjects: 409
Study: 23281831

Group type: EXPERIMENTAL
Intervention: Active VibOS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inactive VibOS
Number of subjects: 10
Study: 21309726

Group type: EXPERIMENTAL
Intervention: Serum UCH-L1 levels
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CSF and serum UCH-L1 levels
Number of subjects: 59
Study: 19609280

Group type: EXPERIMENTAL
Intervention: Dietary sodium and potassium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haplotypes of the WNK1 gene
Number of subjects: 0
Study: 17268411

Group type: EXPERIMENTAL
Intervention: Lutein 18 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lutein 36 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Polyphenols (gallic acid, caffeic acid, (+)‐catechin, naringenin)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carotenoids (lycopene, beta-carotene, lutein)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naringenin
Number of subjects: 8
Study: 15301789

Group type: EXPERIMENTAL
Intervention: 1g/day E-EPA supplementation
Number of subjects: 7
Study: 11376504

Group type: EXPERIMENTAL
Intervention: PDA (Automated Protamine Dose Assay)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Empirical protamine ratio (1 mg protamine/100 U heparin)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PDA and ACT after protamine administration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 50
Study: 9130202

Group type: EXPERIMENTAL
Intervention: Focused stimulation intervention focusing on lexical training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 7945787

Group type: EXPERIMENTAL
Intervention: Oral challenge with aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral challenge with sulfites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral challenge with NSAIDs or food and drug additives
Number of subjects: 0
Study: 3370654

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study: 31856771

Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 75
Study: 28843136

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for BED
Number of subjects: 171
Study: 25392151

Group type: EXPERIMENTAL
Intervention: Nitinol-framed lightweight polypropylene mesh (N-LWM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard lightweight polypropylene mesh (LWM)
Number of subjects: 47
Study: 22703715

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Suboxone
Number of subjects: 71
Study: 21057697

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.4 microg/kg after administration of protamine (group C)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No desmopressin (group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg qd (group B)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg qd (group C)
Number of subjects: 86
Study: 17922971

Group type: EXPERIMENTAL
Intervention: Higher pretreatment hemoglobin (Hb) levels (Hb > or = 12)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: FEV(1) > 2 L
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Higher pretreatment hemoglobin (Hb) values
Number of subjects: 203
Study: 15727952

Group type: EXPERIMENTAL
Intervention: Troglitazone (PPARgamma agonist), 5 microM palmitate, chronic treatment for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Troglitazone (PPARgamma agonist)
Number of subjects: 0
Study: 12556642

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transurethral resection alone (TUR)
Number of subjects: 64
Study: 9654765

Group type: EXPERIMENTAL
Intervention: Momentary coping assessment via palm-top computer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective coping assessment
Number of subjects: 0
Study: 7815846

Group type: EXPERIMENTAL
Intervention: Access to Certified Lactation Consultant (CLC) at Hospital H1
Number of subjects: 161

Group type: COMPARATOR
Intervention: No access to Certified Lactation Consultant (CLC) at Hospital H2
Number of subjects: 161
Study: 2632724

Group type: EXPERIMENTAL
Intervention: 4-6 cups of filtered coffee per day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 4-6 cups of boiled coffee per day
Number of subjects: 107

Group type: COMPARATOR
Intervention: No coffee for a period of 9 weeks
Number of subjects: 107
Study: 4835442

Group type: EXPERIMENTAL
Intervention: 12-hour fast
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-hour fast
Number of subjects: 0
Study: 31900172

Group type: EXPERIMENTAL
Intervention: 14 days of primaquine (0.5 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29870820

Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 122

Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 122
Study: 27362621

Group type: EXPERIMENTAL
Intervention: Standard preprocedure teaching + additional educational intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard preprocedure teaching
Number of subjects: 28
Study: 24967454

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 78
Study: 23488362

Group type: EXPERIMENTAL
Intervention: Post-discharge telephone intervention delivered weekly for the first month and then monthly until the third month (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual community care (control group)
Number of subjects: 40
Study: 20978195

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 639

Group type: COMPARATOR
Intervention: Follow-up only (Control)
Number of subjects: 639
Study: 18617627

Group type: EXPERIMENTAL
Intervention: Exercise training (EX; n = 36)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of exercise training and weight loss (WLEX; n = 17)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weight loss (WL; n = 11)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise training (EX; n = 36) and Combination (WLEX; n = 17)
Number of subjects: 64
Study: 16210715

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated during the first trimester with 30 mg Fe plus 175 microg folic acid
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated during the first trimester with 60 mg Fe plus 350 microg folic acid
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated at week 20 with 30 mg Fe plus 175 microg folic acid
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated at week 20 with 60 mg Fe plus 350 microg folic acid
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 131
Study: 12821469

Group type: EXPERIMENTAL
Intervention: Gentamicin (3 mg/kg/day intravenously for 14 days) and Doxycycline (200 mg/day orally for 28 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gentamicin and Doxycycline (per-protocol analysis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated controls (per-protocol analysis)
Number of subjects: 20
Study: 11143912

Group type: EXPERIMENTAL
Intervention: Induction therapy for PLB
Number of subjects: 28

Group type: COMPARATOR
Intervention: Induction therapy for ESNHL
Number of subjects: 28

Group type: COMPARATOR
Intervention: Induction therapy for SLB
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall survival for PLB
Number of subjects: 28

Group type: COMPARATOR
Intervention: Overall survival for ESNHL
Number of subjects: 28

Group type: COMPARATOR
Intervention: Overall survival for SLB
Number of subjects: 28
Study: 8841903

Group type: EXPERIMENTAL
Intervention: personal instruction
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: self‐education manual
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: video
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: combination of 2 or more modes
Number of subjects: 195

Group type: COMPARATOR
Intervention: various modes of oral hygiene education
Number of subjects: 195
Study: 1617028

Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone in 10 ml NaCl 0.9% (corticoid group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 10 ml NaCl (NaCl group)
Number of subjects: 51
Study: 6541715

Group type: EXPERIMENTAL
Intervention: 400 ml of essential amino acids
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal postoperative electrolyte solutions alone
Number of subjects: 43
Study: 30849300

Group type: EXPERIMENTAL
Intervention: Safe Care, Saving Lives initiative
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison hospitals (control)
Number of subjects: 60
Study: 30212981

Group type: EXPERIMENTAL
Intervention: AML/VAL 5/160 mg FDC
Number of subjects: 238

Group type: COMPARATOR
Intervention: VAL/HCTZ 160/12.5 mg FDC
Number of subjects: 238

Group type: COMPARATOR
Intervention: Comparison between AML/VAL and VAL/HCTZ
Number of subjects: 238
Study: 26704145

Group type: EXPERIMENTAL
Intervention: Moisture Chamber Spectacles (MCS) worn for 90 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received a drop of sterile nonpreserved 0.9% sodium chloride solution
Number of subjects: 30
Study: 24251556

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Educational physiotherapy (E group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 22088556

Group type: EXPERIMENTAL
Intervention: AZD3480 (5 mg, 20 mg, and 35/100 mg depending on CYP2D6 metabolic status)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 21053620

Group type: EXPERIMENTAL
Intervention: Qufeng Zhidong Recipe (TCM group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Haloperidol and trihexyphenidyl (Western medicine group)
Number of subjects: 61
Study: 17639278

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 102
Study: 16290975

Group type: EXPERIMENTAL
Intervention: Inhospital educational intervention delivered by a multidisciplinary team
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 134
Study: 12165970

Group type: EXPERIMENTAL
Intervention: 4-week stress management treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo intervention
Number of subjects: 0
Study: 10066999

Group type: EXPERIMENTAL
Intervention: Aversive conditioning to explicit and contextual cues
Number of subjects: 0
Study: 7720340

Group type: EXPERIMENTAL
Intervention: Right atrioventricular pacing at a rate of 150 impulses/min
Number of subjects: 10
Study: 1759830

Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) single oral dose of 4.5 or 9.0 mg/kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in children from 0.5 to <= 5 years of age
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in children > 10 years of age
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in infants
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in 19 subjects
Number of subjects: 49
Study: 6818599

Group type: EXPERIMENTAL
Intervention: Ethanol administrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test dose of ethanol
Number of subjects: 0
Study: 30669469

Group type: EXPERIMENTAL
Intervention: 140 g of whole blueberries
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo gel (matched for calories, sugars, and fiber)
Number of subjects: 17
Study: 30306796

Group type: EXPERIMENTAL
Intervention: Occupational health education program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 26439782

Group type: EXPERIMENTAL
Intervention: Squat training group (SQ)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Leg-press training group (LP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group for SQ
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group for LP
Number of subjects: 78
Study: 23903975

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 21931983

Group type: EXPERIMENTAL
Intervention: Cued double-step saccade task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saccade execution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial visual and motor processing prior to saccade execution
Number of subjects: 0
Study: 17878209

Group type: EXPERIMENTAL
Intervention: Combination therapy with methotrexate and ciclosporine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Monotherapy with methotrexate and placebo-ciclosporine
Number of subjects: 160
Study: 15894441

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 30
Study: 12605235

Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.05 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.1 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.2 mg
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.3 mg
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 10838535

Group type: EXPERIMENTAL
Intervention: Cardioplegic group with 42 mmol/L glucose and 10 IU/L insulin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cardioplegic group with 84 mmol/L glucose and 10 IU/L insulin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cardioplegic group with 42 mmol/L glucose without insulin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cardioplegic group with 84 mmol/L glucose without insulin
Number of subjects: 56
Study: 9087577

Group type: EXPERIMENTAL
Intervention: Cycle training for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal sedentary activity for 4 weeks
Number of subjects: 13
Study: 8482629

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses of < or = 54 Gy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses > or = 57.6 Gy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses > or = 63 Gy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses 57.6 Gy with a boost of 63 Gy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Dose escalation above 63 Gy at 1.8 Gy per day
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Overall crude and actuarial 2‐year local‐regional recurrence rates
Number of subjects: 302
Study: 3512351

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily for 4 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: 30 mg omeprazole once daily for 4 weeks
Number of subjects: 115
Study: 28975842

Group type: EXPERIMENTAL
Intervention: Two home visits to individualize home exercises
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care including weekly group exercise
Number of subjects: 50
Study: 27624168

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 463

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 463
Study: 24837559

Group type: EXPERIMENTAL
Intervention: Laparoscopic biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 57
Study: 22658785

Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilatory Assist)
Number of subjects: 26

Group type: COMPARATOR
Intervention: SIMV with PS (Synchronized Intermittent Mandatory Ventilation with Pressure Support)
Number of subjects: 26
Study: 20642939

Group type: EXPERIMENTAL
Intervention: Remote ischemic pre-conditioning (rIPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no limb ischemia)
Number of subjects: 100